Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29664764 | 0.94 | TASP1 (0.56) | TASP1FOLH1ALDH1A1PTPN1GNPAT | |
| SCHEMBL29802264 | 0.93 | TASP1 (0.51) | TASP1PTPN1CASP1BACE1BACE2 | |
| SCHEMBL14035809 | 0.91 | GNPAT (0.46) | TASP1FOLH1ALDH1A1PTPN1GNPAT | |
| SCHEMBL29923992 | 0.86 | TASP1 (0.48) | TASP1ALDH1A1PTPN1GNPATCASP1 | |
| SCHEMBL13194679 | 0.85 | CASP1 (0.50) | TASP1GNPATBMP1CASP1BACE1 | |
| SCHEMBL1674857 | 0.85 | CASP1 (0.50) | TASP1GNPATBMP1CASP1BACE1 | |
| SCHEMBL4100803 | 0.85 | CASP1 (0.50) | TASP1GNPATBMP1CASP1BACE1 | |
| SCHEMBL29310042 | 0.85 | CASP1 (0.50) | TASP1GNPATBMP1CASP1BACE1 | |
| SCHEMBL10068454 | 0.85 | CASP1 (0.47) | TASP1GNPATCASP1BACE1BACE2 | |
| SCHEMBL29432579 | 0.84 | REN (0.51) | TASP1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-11525155-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220364149-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885FOLH1 1594/4885ALDH1A1 3862/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885FOLH1 1594/4885ALDH1A1 3862/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885FOLH1 1594/4885ALDH1A1 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.